Figure 1 | Laboratory Investigation

Figure 1

From: Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events

Figure 1

MAOA immunoreactivity in cholangiocarcinoma. Surgically ressected samples from Klatskin and intrahepatic tumors were evaluated for MAOA immunoreactivity and categorized as either strong, moderate, low or none. Choledochal cysts were used as benign controls. (a) Representative photomicrographs of the MAOA staining in each category. (Magnification × 40) (b) The proportion of the samples that were categorized as moderate-to-strong versus none–to-low for each tissue type is depicted. (c) In a subset of clinical samples, tumor tissue was microdissected from the tumor periphery. RNA was extracted and real-time PCR for MAOA was performed. Data are expressed as average±s.d. (n=4; *P<0.05). The survival rate of patients with moderate-to-strong MAOA immunoreactivity versus none-to-low immunoreactivity was assessed for Klatskin tumors (d) and ICC (e).

Back to article page